Evaluation of Collection and Distribution of Samples for Histological, Stereological Analysis and Cell Culture of Canine Mast Cell Tumors

Samanta Rios Melo, Thaís Andrade Costa-Casagrande, Julia Maria Matera

Department of Surgery, School of Veterinary Medicine, University of S?o Paulo, S?o Paulo, Brazil.

DOI: 10.4236/ojvm.2012.24034                

Abstract

Objective: To collect high quality, representative tissue material from tumors and manage its distribution to different laboratories. Design: Prospective controlled study. Animals: Thirty-six dogs with mast cell tumors. Procedures: The samples were submitted for the following analyses: stereology; histopathology; cell culture; breakdown for cytogenetic analysis of chromosomes (based on the Boxer breed published genome); Cell lysis for Real Time PCR and quantification of gene expression of CX 43, 32 and E-cadherin in canine mast cells. Results: Cytogenetic chromosome analysis, 90.9% of the samples were considered to be of good quality. For gene expression quantification of CX 43, 32 and E-cadherin in canine mast cell tumors (MCT), 95.5% of samples were considered to be of good quality. Conclusions and Clinical Relevance: We seek to assess the importance of surgical collection and post-surgical tissue preparation on laboratory testing by collecting surgical material appropriately to allow accurate diagnosis and reliable clinical prognosis and minimize errors caused by inadequate preparation of samples.

Keywords

Mast Cell Tumor; Oncologic Surgery; Canine; Tumor Collection; Stereological Analysis

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	B. Séguin, N. F. Leibman, V. S. Bregazzi, G. K. Ogilvie, B. E. Powers, W. S. Dernell, M. J. Fettman and S. J. Withrow, “Clinical Outcome of Dogs with Grade II Mast Cell Tumors Treated with Surgery Alone: 55 Cases (1996-1999),” Journal of the American Veterinary Medical Association, Vol. 218, No. 7, 2001, pp. 1120-1123. doi:10.2460/javma.2001.218.1120
[2]	D. Slatter, “Textbook of Small Animal Surgery,” 3rd Edition, Elsevier Science, New York, 2002.
[3]	H. D. Thamm and M. D Vail, “Mast Cell Tumors,” In: S. J. Withrow and E. G. Maceven, Small Animal Clinical Oncology, 3rd Edition, Saunders Company, Philadelphia, 2001, pp. 261-282.
[4]	G. M. Michels, D. W. Knapp, D. B. Denicola, N. Glickman and P. Bonney, “Prognosis Following Surgical Excision of Canine Cutaneous Mast Cell Tumors with histopathologically Tumor-Free Versus Nontumor-Free Margins: A Retrospective Study of 31 Cases,” Journal of the American Animal Hospital Association, Vol. 38, No. 5, 2002, pp. 458-466.
[5]	V. M. D. C. Weisse and C. M. V. K. Sorenmo, “Recurrence Rates and Sites for Grade II Canine Cutaneous Mast Cell Tumors Following Complete Surgical Excision,” Journal of the American Animal Hospital Association, Vol. 38, No. 1, 2002, pp. 71-73.
[6]	J. J. Abadie, M. A. Amardeilh and M. E. Delverdier, “Immunohistochemical Detection of Proliferating Cell Nuclear Antigen and Ki-67 in Mast Cell Tumors from Dogs,” Journal of the American Animal Hospital Association, Vol. 215, No. 11, 1999, pp. 1629-1634.
[7]	H. Sakai, A. Noda, N. Shirai, et al., “Proliferative Activity of Canine Mast Cell Tumours Evaluated by Bromodeoxyuridine Incorporation and Ki-67 Expression,” Journal of Comparative Pathology, Vol. 127, No. 4, 2002, pp. 233-238. doi:10.1053/jcpa.2002.0586
[8]	J. P. Simoes, P. Schoning and M. Butine, “Prognosis of Canine Mast Cell Tumors: A Comparison of Three Methods,” Veterinary Pathology, Vol. 31, No. 6, 1994, pp. 637-647. doi:10.1177/030098589403100602
[9]	L. D. Kravis, D. M. Vail, W. C. Kissebert, et al., “Frequency of Argyrophilic Nucleolar Organizer Regions in Fine-Needle Aspirates and Biopsy Specimens from Mast Cell Tumors in Dogs,” Journal of the American Veterinary Medical Association, Vol. 209, No. 8, 1996, pp. 1418-1420.
[10]	R. D. Ayl, C. G. Couto, A. S. Hammer, S. Weisbrode, J. G. Ericson and L. Mathes, “Correlation of DNA Ploidy to Tumor Histologic Grade, Clinical Variables, and Survival in Dogs with Mast Cell Tumors,” Veterinary Pathology, Vol. 29, No. 5, 1992, pp. 386-390. doi:10.1177/030098589202900503
[11]	R. Preziosi, G. Sarli and M. Paltrinieri, “Prognostic Value of Intratumoral Vessel Density in Cutaneous Mast Cell Tumors of the Dog,” Journal of Comparative Pathology, Vol. 130, No. 2-3, 2004, pp. 143-151. doi:10.1016/j.jcpa.2003.10.003
[12]	P. E. Ginn, L. E. Fox, J. C. Brower, A. Gaskin, I. D. Kurzman and P. S. Kubilis, “Immunohistochemical Detection of p53 Tumor-Suppressor Protein Is a Poor Indicator of Prognosis for Canine Cutaneous Mast Cell Tumors,” Veterinary Pathology, Vol. 37, No. 1, 2000, pp. 33-39. doi:10.1354/vp.37-1-33
[13]	M. H. Jaffe, G. Hosgood, H. W. Taylor, S. C Kerwin, C. S. Hedlund, M. K. Lopez, J. R. Davidson, D. M. Miller and M. Paranjpe, “Immunohistochemical and Clinical Evaluation of p53 in Canine Cutaneous Mast Cell Tumors,” Veterinary Pathology, Vol. 37, No. 1, 2000, pp. 40-46. doi:10.1354/vp.37-1-40
[14]	M. Kiupel, J. D. Webster, J. B. Kaneene, et al., “The Use of KIT and Tryptase Expression Patterns as Prognostic Tools for Canine Cutaneous Mast Cell Tumors,” Veterinary Pathology, Vol. 41, No. 4, 2004, pp. 371-377. doi:10.1354/vp.41-4-371
[15]	J. D. Webster, V. Yuzbasiyan-Gurkan, J. B. Kaneene, et al., “The Role of c-KIT in Tumorigenesis: Evaluation in Canine Cutaneous Mast Cell Tumors,” Neoplasia, Vol. 8, No. 2, 2006, pp. 104-111. doi:10.1593/neo.05622
[16]	R. F. Strefezzi, G. J. Xavier and J. L. Catao-Dias, “Morphometry of Canine Cutaneous Mast Cell Tumors,” Veterinary Pathology, Vol. 40, No. 3, 2003, pp. 268-275. doi:10.1354/vp.40-3-268
[17]	M. Kiupel, J. D. Webster, R. A. Miller and J. B. Kaneene, “Impact of Tumour Depth, Tumour Location and Multiple Synchronous Masses on the Prognosis of CANINE cutaneous Mast Cell Tumours,” Journal of Veterinary Medicine Series A, Vol. 52, No. 6, 2005, pp. 280-286. doi:10.1111/j.1439-0442.2005.00726.x
[18]	A. K. Cahalane, S. Payne, L. G. Barber, et al., “Prognostic Factors for Survival of Dogs with Inguinal and Perineal Mast Cell Tumors Treated Surgically with or without Adjunctive Treatment: 68 Cases (1994-2002),” Journal of the American Veterinary Medical Association, Vol. 225, No. 3, 2004, pp. 401-408. doi:10.2460/javma.2004.225.401
[19]	A. K. Patnaik, W. J. Ehler and E. G. Macewen, “Canine Cutaneous Mast Cell Tumor: Morphologic Grading and Survival Time in 83 Dogs,” Veterinary Pathology, Vol. 21, No. 5, 1984, pp. 469-474.
[20]	S. S. Raab, R. E. Nakhleh and S. G. Ruby, “Patient Safety in Anatomic Pathology: Measuring Discrepancy Frequencies and Causes,” Archives of Pathology & Laboratory Medicine, Vol. 129, No. 4, 2005, pp. 459-466.
[21]	S. S. Raab, D. M. Grzybicki, J. E. Janosky et al., “Clinical Impact and Frequency of Anatomic Pathology Erros in Cancer Diagnosis,” American Cancer Society, Vol. 104, No. 10, 2005, pp. 2205-2213.
[22]	S. S. Raab, “Improving Patient Safety by Examining Pathology Errors,” Clinics in Laboratory Medicine, Vol. 24, No. 4, 2004, pp. 849-886. doi:10.1016/j.cll.2004.05.014
[23]	K. Lindblad-Toh, C. M. Wade, T. S. Mikkelsen, E. K. Karlsson, D. B. Jaffe, M. Kamal, M. Clamp, J. L. Chang, E. J. Kulbokas, M. C. Zody, et al., “Genome Sequence, Comparative Analysis and Haplotype Structure of the Domestic Dog,” Nature, Vol. 438, No. 7069, 2005, pp. 803-819. doi:10.1038/nature04338
[24]	M. H. Goldschmidt and M. J. Hendrick, “Tumors of the Skin and Soft Tissues,” In: D. J. Meuten, “Tumors in Domestic Animals,” 4th Edition, Iowa State Press, Iowa, 2002, pp. 105-107. doi:10.1002/9780470376928.ch2
[25]	J. M. Cullen, R. Page and W. Misdorp, “An Overview of Cancer Pathogenesis, Diagnosis, and Management,” In: D. J. Meuten, “Tumors in Domestic Animals,” 4th Edition, Iowa State Press, Iowa, 2002, pp. 3-27.
[26]	K. S. Rogers, “Mast Cell Tumors: Dilemmas of Diagnosis and Treatment,” Veterinary Clinics of North America, Vol. 26, No. 1, 1996, pp. 87-102.